AURX NUO THERAPEUTIC

$1.25

NUO THERAPEUTIC (AURX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with AURX's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 1 buyer in the last 30 days 1 buyer in the last 90 days 0 sellers in the last 90 days
Insiders buying
1
2 transactions
Insiders selling
1
1 transaction
Purchases
$9.5K
8,773 shares
Sales
$300.0K
200,000 shares
Net activity
-$290.5K
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $300.0K 1 transaction · 200,000 shares

Largest single sale: $300.0K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: August 28, 2026 , by JORDEN DAVID EMERSON .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
JORDEN DAVID EMERSON CEO/CFO Buy 7,984 $1.09 $8.7K 2,070,000
JORDEN DAVID EMERSON CEO/CFO Buy 789 $1.07 $844 2,062,016
JORDEN DAVID EMERSON CEO/CFO Sell 200,000 $1.50 $300.0K 1,946,755 −9.3% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.